- ￥2000
- ImmuneChem
- ICP9705
- 加拿大
- 2025年07月27日
- 其它
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 抗体英文名：
Mouse IgG Antibody, Agarose
- 宿主：
其它
- 供应商：
上海研卉生物科技有限公司
- 库存：
大量
- 抗原来源：
其它
- 是否单克隆：
0
- 规格：
2ml
Mouse IgG Antibody, Agarose 的详细介绍
- 类 型：各种亲和填料
Catalog Number Pack Size Price(CNY)
ICP9705 2 mL ￥2000.00
Product Description: Monoclonal antibody production using cell culture system sometime requires the use of fetal calf serum. Purification of the mouse ntibody from the cell culture supernatant using Protein A/G system may result in contamination of bovine IgG. “Mouse IgG antibody , Agarose” is the mouse IgG-specific affinity matrix that could selectively purify mouse IgG from the supernatant of the cell cultre media without pulling-down the bovine IgG at the same tme. This “Mouse IgG antibody, Agarose” is prepared using antigen-specific affinity purified mouse IgG antibody as immoblized antodies. More than 15 mg of pure mouse IgG antibody was covalently immobilized onto the Agarose beads via a highly stable thiol-ether bond. This product has been successfully used to replace “Protein A/G Agarose” for more specific affinity purification of mouse IgG with high binding capacity (> 2mg/mL).
Formulation: 2 mL in 4 mL PBS with 70% Glycerol.
Storage & Stability: Store product at –20 ℃. Three years from date of shipping.
Ligand Immobilized: 10-15 mg mouse IgG antibody / mL
Binding Capacity: >2 mg/mL of mouse IgG
Applications: Immuno-Affinity Chromatography, Immunoprecipitation.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Bispecific Antibody Derivatives Based on Full-Length IgG Formats
improvements were made in protein engineering during the last years. This allows the design of several new IgG-based bispecific antibody formats that can be prepared in high yields and high homogeneity using conventional expression and purification techniques
in the development of BsAb has been the difficulty of producing the materials in sufficient quality and quantity by traditional technologies such as the hybrid hybridoma and chemical conjugation methods. The development of IgG-like BsAbs as therapeutic agents
of the constructs (or formats) and production efficiency. Here we describe a recombinant method for the construction and production of a tetravalent IgG-like BsAb molecule, IgG–scFv fusion, in which, a single-chain Fv (scFv) antibody fragment of one antigen
技术资料暂无技术资料 索取技术资料
